Brief: Xeris Biopharma Subsidiaries File Recorlev Patent Infringement Lawsuit
26/02/2026 23:01
Feb 26 (Reuters) - Xeris Biopharma Holdings Inc XERS.O: XERIS BIOPHARMA SUBSIDIARIES FILE RECORLEV® PATENT INFRINGEMENT LAWSUIT XERIS BIOPHARMA HOLDINGS INC: INTENDS TO ENFORCE AND DEFEND ITS INTELLECTUAL PROPERTY RIGHTS RELATING TO RECORLEV XERIS BIOPHARMA HOLDINGS: FILED PATENT INFRINGEMENT LAWSUIT RELATED TO RECORLEV AGAINST TORRENT PHARMACEUTICALS & SOMERSET THERAPEUTICS Source text: ID:nBw3PrKyCa Further company coverage: XERS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xeris Biopharma Holdings
See all newsBrief: Xeris Biopharma Announces Private Exchange Of Convertible Notes
Xeris Biopharma Q1 product revenue jumps 43%, beats estimates
Brief: Xeris Biopharma Q4 Product Revenue USD 83.43 Million Versus. Ibes Estimate USD 82.3 Million
Xeris Biopharma Q4 product revenue beats analyst expectations, driven by higher patient demand
Brief: Xeris Biopharma Subsidiaries File Recorlev Patent Infringement Lawsuit